119 related articles for article (PubMed ID: 38151388)
41. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
[TBL] [Abstract][Full Text] [Related]
42. EuroQOL-5D-3L does not adequately map quality-of-life deterioration in severely affected patients with epilepsy.
Willems LM; Knake S; Rosenow F; Reese JP; Conradi N; Strzelczyk A
Epilepsy Behav; 2022 Feb; 127():108554. PubMed ID: 35063789
[TBL] [Abstract][Full Text] [Related]
43. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
44. Physiotherapist as primary assessor for patients with suspected knee osteoarthritis in primary care-a randomised controlled pragmatic study.
Ho CM; Thorstensson CA; Nordeman L
BMC Musculoskelet Disord; 2019 Jul; 20(1):329. PubMed ID: 31301739
[TBL] [Abstract][Full Text] [Related]
45. Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect
Sharman JP; Cocks K; Nabhan C; Lamanna N; Kay NE; Grinblatt DL; Flowers CR; Davids MS; Kiselev P; Swern AS; Sullivan K; Gharibo MM; Flick ED; Trigg A; Mato A
EJHaem; 2020 Jul; 1(1):188-198. PubMed ID: 35847738
[TBL] [Abstract][Full Text] [Related]
46. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
47. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
48. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
49. Catalog of EQ-5D-3L Health-Related Quality-of-Life Scores for 199 Chronic Conditions and Health Risks in Denmark.
Hvidberg MF; Petersen KD; Davidsen M; Witt Udsen F; Frølich A; Ehlers L; Alava MH
MDM Policy Pract; 2023; 8(1):23814683231159023. PubMed ID: 37056295
[TBL] [Abstract][Full Text] [Related]
50. Health inequity assessment in Brazil: is EQ-5D-3L sensible enough to detect differences among distinct socioeconomic groups?
Tura BR; da Costa MR; Lordello S; Barros D; Souza Y; da Silva Santos M
Health Qual Life Outcomes; 2024 Feb; 22(1):22. PubMed ID: 38409033
[TBL] [Abstract][Full Text] [Related]
51. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
[No Abstract] [Full Text] [Related]
52. Evaluation of the EQ-5D-3L and 5L versions in low back pain patients.
Garratt AM; Furunes H; Hellum C; Solberg T; Brox JI; Storheim K; Johnsen LG
Health Qual Life Outcomes; 2021 May; 19(1):155. PubMed ID: 34049574
[TBL] [Abstract][Full Text] [Related]
53. Health-related quality of life in residents aged 18 years and older with and without disease: findings from the First Provincial Health Services Survey of Hunan, China.
Deng X; Dong P; Zhang L; Tian D; Zhang L; Zhang W; Li L; Deng J; Ning P; Hu G
BMJ Open; 2017 Sep; 7(9):e015880. PubMed ID: 28871016
[TBL] [Abstract][Full Text] [Related]
54. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Montillo M; Illés Á; Robak T; Pristupa AS; Wach M; Egyed M; Delgado J; Jurczak W; Morschhauser F; Schuh A; Eradat H; Shreay S; Barrientos JC; Zelenetz AD
Health Qual Life Outcomes; 2019 Nov; 17(1):173. PubMed ID: 31729982
[TBL] [Abstract][Full Text] [Related]
55. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Abramson JS; Johnston PB; Kamdar M; Ibrahimi S; Izutsu K; Arnason J; Glass B; Mutsaers P; Lunning M; Braverman J; Liu FF; Crotta A; Montheard S; Previtali A; Guo S; Shi L; Solomon SR
Blood Adv; 2022 Dec; 6(23):5969-5979. PubMed ID: 36149968
[TBL] [Abstract][Full Text] [Related]
56. Health-related quality of life in HIV/AIDS patients on antiretroviral therapy at a tertiary care facility in Zimbabwe.
Mafirakureva N; Dzingirai B; Postma MJ; van Hulst M; Khoza S
AIDS Care; 2016 Jul; 28(7):904-12. PubMed ID: 27098289
[TBL] [Abstract][Full Text] [Related]
57. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
[TBL] [Abstract][Full Text] [Related]
58. The predictive ability of EQ-5D-3L compared to the LACE index and its association with 30-day post-hospitalization outcomes.
Al Sayah F; McAlister FA; Ohinmaa A; Majumdar SR; Johnson JA
Qual Life Res; 2021 Sep; 30(9):2583-2590. PubMed ID: 33974221
[TBL] [Abstract][Full Text] [Related]
59. A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma.
Liu FF; Bartlett M; Craigie S
Pharmacoecon Open; 2024 Mar; 8(2):171-190. PubMed ID: 38198111
[TBL] [Abstract][Full Text] [Related]
60. Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L.
Rand K; Arnevik EA; Walderhaug E
J Patient Rep Outcomes; 2020 Nov; 4(1):92. PubMed ID: 33165764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
